CD248: Reviewing its role in health and disease

Current Drug Targets

Volumn 13, Issue 3, 2012, Pages 432-439

  Valdez, Yanet ^a   Maia, Margarida ^b   Conway, Edward M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cancer; Endosialin; Fibroblast; Inflammation; Pericytes; Stromal cells

Indexed keywords

ENDOSIALIN;

ARTHRITIS; BINDING AFFINITY; CYTOPLASM; GENE CONTROL; HUMAN; MEDICAL LITERATURE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SALMONELLOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MOLECULAR SEQUENCE DATA; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857135316     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799424615     Document Type: Review

References (58)

1. Rettig WJ, Garin-Chesa P, Healey JH, et al. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 1992; 89(22): 10832-10836.
2. Carson-Walter EB, Watkins DN, Nanda A, et al. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001; 61(18): 6649-6655.
3. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289(5482): 1197-1202.
4. MacFadyen J, Savage K, Wienke D, Isacke CM. Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouseembryos and is downregulated during development. Gene Expr Patterns 2007; 7(3): 363-369.
5. Rupp C, Dolznig H, Puri C, et al. Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun 2006; 6: 10.
6. Rouleau C, Curiel M, Weber W, et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res 2008; 14(22): 7223-7236.
7. Huber MA, Kraut N, Schweifer N, et al. Expression of stromal cell markers in distinct compartments of human skin cancers. J CutanPathol 2006; 33(2): 145-155.
8. Brady J, Neal J, Sadakar N, Gasque P. Human end osialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol 2004; 63(12): 1274-1283.
9. Simonavicius N, Robertson D, Bax DA, et al. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 2008; 21(3): 308-315.
10. Christian S, Winkler R, Helfrich I, et al. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vesselassociated mural cells. Am J Pathol 2008; 172(2): 486-494.
11. MacFadyen JR, Haworth O, Roberston D, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett 2005; 579(12): 2569-2575.
12. Maia M, de Vriese A, Janssens T, et al. CD248 and its cytoplasmic domain: a therapeutic target for arthritis. Arthritis Rheum 2010; 62(12): 3595-3606.
13. Van de Wouwer M, Collen D, Conway EM. Thrombomodulinprotein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24(8): 1374-1383.
14. Greenlee MC, Sullivan SA, Bohlson SS. CD93 and related family members: their role in innate immunity. Curr Drug Targets 2008; 9(2): 130-138.
15. Christian S, Ahorn H, Koehler A, et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001; 276(10): 7408-7414.
16. Opavsky R, Haviernik P, Jurkovicova D, et al. Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J Biol Chem 2001; 276(42): 38795-38807.
17. Ohradanova A, Gradin K, Barathova M, et al. Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. Br J Cancer 2008; 99(8): 1348-1356.
18. Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. FEBS J 2005; 272(24): 6179-6217.
19. Van de Wouwer M, Conway EM. Novel functions of thrombomodulin in inflammation. Crit Care Med 2004; 32(5 Suppl): S254-S261.
20. Nangaku M. Complement regulatory proteins in glomerular diseases. Kidney Int 1998; 54(5): 1419-1428.
21. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361(17): 1676-1687.
22. Abrera-Abeleda MA, Nishimura C, Smith JL, et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membrano prolix ferative glomerulone phritis type II (dense deposit disease). J Med Genet 2006; 43(7): 582-589.
23. Richards SJ, Hill A, Hillmen P. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry 2007; 72(5): 291-298.
24. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16(5): 1392-1403.
25. Nourry C, Grant SG, Borg JP. PDZ domain proteins: plug and play Sci STKE 2003; 2003(179): RE7.
26. Dev KK. Making protein interactions druggable: targeting PDZ domains. Nat Rev Drug Discov 2004; 3(12): 1047-1056.
27. Tomkowicz B, Rybinski K, Foley B, et al. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci USA 2007; 104(46): 17965-17970.
28. Becker R, Lenter MC, Vollkommer T, et al. Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. FASEB J 2008; 22(8): 3059-3067.
29. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002; 13(1): 75-85.
30. Maia M, Devriese A, Janssens T, et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer 2011; 11(1): 162.
31. Bagley RG. Endosialin: from vascular target to biomarker for human sarcomas. Biomark Med 2009; 3(5): 589-604.
32. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8(9): 726-736.
33. Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4(4): e4992.
34. Carson-Walter EB, Winans BN, Whiteman MC, et al. Characterization of TEM1/endosialin in human and murine brain tumors. BMC Cancer 2009; 9: 417.
35. Lax S, Hou TZ, Jenkinson E, et al. CD248/Endosialin is dynamically expressed on a subset of stromal cells during lymphoid tissue development, splenic remodeling and repair. FEBS Lett 2007; 581(18): 3550-3556.
36. Huang HP, Hong CL, Kao CY, et al. Gene targeting and expression analysis of mouse Tem1/endosialin using a lacZ reporter. Gene Expr Patterns 2011; 11(5-6): 316-326.
37. Nanda A, Karim B, Peng Z, et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci USA 2006; 103(9): 3351-3356.
38. Dolznig H, Schweifer N, Puri C, et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 2005; 5: 10.
39. Bagley RG, Honma N, Weber W, et al. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc Res 2008; 76(3): 180-188.
40. Virgintino D, Girolamo F, Errede M, et al. An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis. Angiogenesis 2007; 10(1): 35-45.
41. Hardie DL, Baldwin MJ, Naylor A, et al. The stromal cell antigen CD248 (endosialin) is expressed on naive CD8(+) human T cells and regulates proliferation. Immunology 2011; 133(3): 288-295.
42. Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis 2004; 21(1): 31-37.
43. Teicher BA. Newer vascular targets: endosialin (review). Int J Oncol 2007; 30(2): 305-312.
44. Rouleau C, Smale R, Fu YS, et al. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. Int J Oncol 2011; 39(1): 73-89.
45. Smith SW, Eardley KS, Croft AP, et al. CD248(+) stromal cells are associated with progressive chronic kidney disease. Kidney Int 2011; 80(2): 199-207.
46. Conejo-Garcia JR, Buckanovich RJ, Benencia F, et al. Vascular leukocytes contribute to tumor vascularization. Blood 2005; 105(2): 679-681.
47. Bagley RG, Rouleau C, St Martin T, et al. Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther 2008; 7(8): 2536-2546.
48. Bagley RG, Weber W, Rouleau C, et al. Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int J Oncol 2009; 34(3): 619-627.
49. Lax S, Hardie DL, Wilson A, et al. The pericyte and stromal cell marker CD248 (endosialin) is required for efficient lymph node expansion. Eur J Immunol 2010; 40(7): 1884-1849.
50. Tomkowicz B, Rybinski K, Sebeck D, et al. Endosialin/TEM- 1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biol Ther 2010; 9(11): 908-915.
51. Dotto GP. Notch tumor suppressor function. Oncogene 2008; 27(38): 5115-5123.
52. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008; 27(38): 5132-5137.
53. Sang L, Roberts JM, Coller HA. Hijacking HES1: how tumors coopt the anti-differentiation strategies of quiescent cells. Trends MolMed 2010; 16(1): 17-26.
54. Villaronga MA, Lavery DN, Bevan CL, Llanos S, Belandia B. HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions. Oncogene 2010; 29(3): 411-420.
55. Yeo M, Park HJ, Kim DK, et al. Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppressescolon tumorigenicity in vivo and in vitro. Cancer 2010; 116(11): 2581-2589.
56. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophilmediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196(5): 565-577.
57. Van de Wouwer M, Plaisance S, De Vriese A, et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4(8): 1813-1824.
58. Zhao A, Nunez-Cruz S, Li C, et al. Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. J Immunol Methods 2011; 363(2): 221-232.